{"id":"heparin-or-bivalirudin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding"},{"rate":"1-3","effect":"Thrombocytopenia"},{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Hyperkalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Heparin is an indirect thrombin inhibitor that works through antithrombin III to inactivate factors IIa and Xa in the coagulation cascade. Bivalirudin is a direct thrombin inhibitor that binds directly to thrombin's active site and fibrin-binding site, preventing clot formation. Both are used to prevent thrombotic events in acute coronary syndromes and during percutaneous coronary intervention.","oneSentence":"Heparin and bivalirudin are anticoagulants that prevent blood clot formation by inhibiting thrombin and other coagulation factors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:34.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Percutaneous coronary intervention"},{"name":"Venous thromboembolism prophylaxis and treatment"},{"name":"Atrial fibrillation for stroke prevention"}]},"trialDetails":[{"nctId":"NCT06080074","phase":"PHASE2","title":"Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-04-15","conditions":"Heart Failure, Cardiogenic Shock, Congenital Heart Disease","enrollment":50},{"nctId":"NCT03537586","phase":"NA","title":"A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2018-06-29","conditions":"Coronary Microvascular Disease, Ischemic Heart Disease, Myocardial Ischemia","enrollment":206},{"nctId":"NCT06275555","phase":"NA","title":"Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","status":"RECRUITING","sponsor":"Xiaotong Hou","startDate":"2024-06-03","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":154},{"nctId":"NCT03664180","phase":"PHASE4","title":"Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI","status":"COMPLETED","sponsor":"Beijing Anzhen Hospital","startDate":"2019-01-11","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":2989},{"nctId":"NCT01270139","phase":"NA","title":"Plasmonic Nanophotothermal Therapy of Atherosclerosis","status":"COMPLETED","sponsor":"Ural State Medical University","startDate":"2007-04-01","conditions":"Stable Angina, Heart Failure, Atherosclerosis","enrollment":180},{"nctId":"NCT03707418","phase":"PHASE1","title":"Bivalirudin vs Heparin in ECMO Patients","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2021-04","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":""},{"nctId":"NCT02618837","phase":"PHASE4","title":"Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2015-12-14","conditions":"Unstable Angina or Non ST Elevated Myocardial Infarction","enrollment":2520},{"nctId":"NCT03882775","phase":"PHASE4","title":"Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2019-01-16","conditions":"STEMI, Percutaneous Coronary Intervention, Aged","enrollment":240},{"nctId":"NCT00073580","phase":"PHASE3","title":"Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-10","conditions":"Thrombocytopenia, Thrombosis, Cardiac Disease","enrollment":88},{"nctId":"NCT01245725","phase":"PHASE3","title":"Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention","status":"WITHDRAWN","sponsor":"Medicure","startDate":"","conditions":"Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina","enrollment":""},{"nctId":"NCT01084993","phase":"PHASE4","title":"EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of Bleeding","status":"UNKNOWN","sponsor":"Laval University","startDate":"2010-03","conditions":"Coronary Artery Disease","enrollment":2000},{"nctId":"NCT00433966","phase":"PHASE3","title":"Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Cardiovascular Research Foundation, New York","startDate":"2005-03","conditions":"Myocardial Infarction","enrollment":3602},{"nctId":"NCT01913483","phase":"PHASE3","title":"ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial","status":"TERMINATED","sponsor":"The Medicines Company","startDate":"2013-09-24","conditions":"Peripheral Endovascular Interventions, Bleeding","enrollment":732},{"nctId":"NCT02311231","phase":"PHASE4","title":"Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2014-06","conditions":"ST-segment Elevation Myocardial Infarction, Non ST-segment Elevation Myocardial Infarction","enrollment":6012},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT01433627","phase":"PHASE3","title":"Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX","status":"UNKNOWN","sponsor":"Italian Society of Invasive Cardiology","startDate":"2011-10","conditions":"Acute Coronary Syndromes, STEMI, NSTEMI","enrollment":7200},{"nctId":"NCT01464671","phase":"PHASE4","title":"Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2009-07","conditions":"Coronary Artery Disease","enrollment":260},{"nctId":"NCT00464087","phase":"PHASE3","title":"Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"2007-06","conditions":"Acute Coronary Syndromes","enrollment":100},{"nctId":"NCT00079508","phase":"PHASE3","title":"Angiomax in Patients With HIT/HITTS Type II Undergoing CPB","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2004-04","conditions":"Cardiovascular Disease, Coronary Artery Bypass Surgery","enrollment":125},{"nctId":"NCT00073593","phase":"PHASE3","title":"Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-08","conditions":"Cardiac Surgery, Coronary Artery Bypass Surgery","enrollment":150},{"nctId":"NCT00398463","phase":"PHASE4","title":"Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2006-05","conditions":"Angioplasty, Transluminal, Percutaneous Coronary","enrollment":263},{"nctId":"NCT01157455","phase":"PHASE4","title":"A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization","status":"UNKNOWN","sponsor":"CCRF Consulting Co., Ltd.","startDate":"2010-05","conditions":"Coronary Artery Diseases","enrollment":1900},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570},{"nctId":"NCT00093158","phase":"PHASE3","title":"Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2003-08","conditions":"Unstable Angina, Myocardial Infarction, Acute Disease","enrollment":13800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Heparin or Bivalirudin","genericName":"Heparin or Bivalirudin","companyName":"CCRF Consulting Co., Ltd.","companyId":"ccrf-consulting-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Heparin and bivalirudin are anticoagulants that prevent blood clot formation by inhibiting thrombin and other coagulation factors. Used for Acute coronary syndrome, Percutaneous coronary intervention, Venous thromboembolism prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}